Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

EVAGGELISMOS"General Hospital of Athens

Verified siteinfo

Greece Ipsiladou 45-47, 106 76 Athens, Greece

  • 21 trials recruiting
  • Plasma cell myeloma · Colitis ulcerative · Crohn's disease
  • Adults and children

About Specializations

EVAGGELISMOS"General Hospital of Athens in Athens, Greece specialises in clinical trials of conditions such as Plasma cell myeloma, Colitis ulcerative, Crohn's disease, Acute myeloid leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Hematologic Oncology

The medical center is at the forefront of hematologic oncology, focusing on innovative treatments for blood cancers. The ongoing research is dedicated to improving outcomes for patients with challenging conditions such as Acute Myeloid Leukemia (AML).

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndromes (MDS)
  • Relapsed/Refractory Blood Cancers

Through cutting-edge clinical trials, the center is exploring new therapeutic agents like AB8939, aiming to enhance the safety and efficacy of treatments for patients with relapsed or refractory AML. This research is pivotal in establishing new standards of care and expanding treatment options for hematologic malignancies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ipsiladou 45-47106 76 AthensGreece
Open in maps ↗
Recruiting now
21 trials
Conditions studied
36
Partner status
Verified site

More sites in AthensGreece

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

60 clinical trials

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Plasma cell myeloma

Recruiting

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:F. Hoffmann-La Roche AG

Chronic myeloid leukaemia

Recruiting

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Plasma cell myeloma refractory

Recruiting

A study of the safety and effectiveness of REGN17372 and linvoseltamab in adults with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Regeneron Pharmaceuticals Inc.

Acute myeloid leukaemia+1

Recruiting

A Study of Gilteritinib to Eliminate Remaining Cancer Cells in Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hellenic Society Of Hematology

Plasma cell myeloma refractory

Recruiting

Study of mezigdomide and elranatamab combination treatment for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celgene Corp.

Graves' disease

Recruiting

Study of IMVT-1402 Treatment for Adults with Graves' Disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Follicular lymphoma

Recruiting

Study Comparing Golcadomide and Rituximab with Other Treatments for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Celgene Corp.

Colitis ulcerative+1

Recruiting

Study on Long-term Safety of Zasocitinib for Adults with Moderate to Severe Ulcerative Colitis and Crohn's Disease

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Plasma cell myeloma refractory

Recruiting

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.